NCT04822701View on ClinicalTrials.gov

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

July 2, 2021

Study Completion Date

October 4, 2021

Conditions
COVID-19
Interventions
DRUG

BI 767551 intravenous

BI 767551 intravenous

DRUG

BI 767551 inhaled

BI 767551 inhaled

DRUG

Placebo intravenous

Placebo intravenous

DRUG

Placebo inhaled

Placebo inhaled

Trial Locations (5)

28031

Hospital Universitario Infanta Leonor, Madrid

33166

Ocean Blue Medical Research Center, Inc., Miami Springs

77027

Advanced Surgeons and Physicians Network, Houston

77904

Crossroads Clinical Research, Victoria

79109

Pharmatex Research, Amarillo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04822701 - A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19 | Biotech Hunter | Biotech Hunter